GlassScriptPhysician profile
Amethyst Wilder
NPI 1396168753
$2,095.06
in general payments reported to CMS, 2019-2025
21 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.46 · 2020: $153 · 2021: $143 · 2022: $44.14 · 2023: $18.23 · 2024: $206 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,240 · Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,240.00 |
| Food and Beverage | $447.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,414.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $82.35 | 2020-2021 | |
| Lilly USA, LLC | $65.64 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Organon LLC | $61.61 | 2022-2024 | Nexplanon |
| Vanda Pharmaceuticals INC. | $57.61 | 2025 | Fanapt |
| Novo Nordisk INC | $41.13 | 2021-2025 | Ozempic |
| Zealand Pharma US, INC. | $36.63 | 2020 | |
| Dexcom, INC. | $35.05 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $34.53 | 2020 | |
| Sanofi-Aventis U.S. LLC | $30.27 | 2025 | |
| Exact Sciences Corporation | $29.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $28.93 | 2019 | |
| Inspire Medical Systems, INC. | $26.84 | 2025 | Inspire |
| Abiomed | $23.43 | 2024 | Impella |
| Abbott Laboratories | $21.79 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.30 | 2021 | |
| Vifor Pharma, INC. | $21.25 | 2021 | |
| Global Blood Therapeutics, INC. | $18.54 | 2020 | |
| Redhill Biopharma INC. | $18.14 | 2020 | |
| Esperion Therapeutics, INC. | $14.67 | 2021 | |
| Amarin Pharma, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amethyst Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.